NeuroSense Therapeutics Ltd.
NRSN
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is an oral combination therapy designed for amyotrophic lateral sclerosis (ALS), while its broader pipeline includes research programs for Alzheimer’s disease and Parkinson’s disease. The company develops targeted therapeutic approaches intended to address complex neurological conditions with significant unmet medical need. NeuroSense Therapeutics Ltd. operates in the global biopharmaceutical market, where it contributes to the advancement of novel drug candidates through clinical and preclinical development. Based in Herzliya, Israel, the company is positioned within the specialized field of neuroscience-focused drug discovery and development.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$11M
▼ -9.0% YoY
Op. Margin
–
ROIC
-619.76%
▼ -60.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▲ +24.3% YoY
Op. Cash Flow (TTM)
-$8M
▲ +24.3% YoY
Net Debt
$4K
Cash & Equiv.
$166K
Continue Research
Peers
Biotechnology · Pick stocks to compare with NRSN
NeuroSense Therapeutics (NRSN) in three numbers
Questions about NeuroSense Therapeutics
Is NeuroSense Therapeutics a high-quality business?
NeuroSense Therapeutics scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is share count change at 121.5%. The Quality tab shows every check against its target.
Does NeuroSense Therapeutics (NRSN) pay a dividend?
No. NeuroSense Therapeutics (NRSN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NRSN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.